Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
JAGX Jaguar Health Inc
- Stocks
- Healthcare
- NASDAQ: JAGX
Price (delayed)
$5.88
Market cap
$5.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$152.39
Enterprise value
$38.63M
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating
Highlights
The company's revenue rose by 14% YoY
JAGX's gross margin is up by 4% year-on-year
The EPS has soared by 85% YoY but it fell by 17% QoQ
Jaguar Health's gross profit has increased by 19% YoY but it has decreased by 2.3% QoQ
The equity has shrunk by 85% YoY and by 76% QoQ
JAGX's quick ratio has dropped by 67% year-on-year and by 49% since the previous quarter
Key stats
What are the main financial stats of JAGX
Market
Valuations
Earnings
Shares outstanding
1.02M
Market cap
$5.99M
Enterprise value
$38.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
0.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.34
Revenue
$11.55M
Gross profit
$9.51M
Operating income
-$32.04M
Net income
-$39.73M
EBIT
-$40.17M
EBITDA
-$37.87M
Free cash flow
-$29.65M
Per share
Balance sheet
Liquidity
EPS
-$152.39
EPS diluted
-$152.39
Free cash flow per share
-$47.32
Book value per share
$2.64
Revenue per share
$18.43
TBVPS
$53.38
Total assets
$51.46M
Total liabilities
$48.15M
Debt
$38.34M
Equity
$1.78M
Working capital
$2.23M
Debt to equity
21.51
Current ratio
1.08
Quick ratio
0.25
Net debt/EBITDA
-0.86
Margins
Efficiency
Dividend
EBITDA margin
-327.8%
Gross margin
82.3%
Net margin
-343.9%
Operating margin
-277.3%
Return on assets
-70.7%
Return on equity
-401.5%
Return on invested capital
-98.4%
Return on capital employed
-172.7%
Return on sales
-347.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAGX stock price
How has the Jaguar Health stock price performed over time
Intraday
6.91%
1 week
-30.9%
1 month
4.79%
1 year
-98.63%
YTD
-76.71%
QTD
23.53%
Financial performance
How have Jaguar Health's revenue and profit performed over time
Revenue
$11.55M
Gross profit
$9.51M
Operating income
-$32.04M
Net income
-$39.73M
Gross margin
82.3%
Net margin
-343.9%
Jaguar Health's gross profit has increased by 19% YoY but it has decreased by 2.3% QoQ
The company's revenue rose by 14% YoY
JAGX's operating margin is up by 14% YoY but it is down by 5% from the previous quarter
JAGX's net margin is up by 9% year-on-year but it is down by 4.4% since the previous quarter
Price vs fundamentals
How does JAGX's price correlate with its fundamentals
Growth
What is Jaguar Health's growth rate over time
Valuation
What is Jaguar Health stock price valuation
P/E
N/A
P/B
2.22
P/S
0.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.34
The EPS has soared by 85% YoY but it fell by 17% QoQ
The equity has shrunk by 85% YoY and by 76% QoQ
The price to book (P/B) is 59% higher than the last 4 quarters average of 1.4 but 50% lower than the 5-year quarterly average of 4.4
The price to sales (P/S) is 94% lower than the 5-year quarterly average of 5.6 and 54% lower than the last 4 quarters average of 0.7
The company's revenue rose by 14% YoY
Efficiency
How efficient is Jaguar Health business performance
The ROE is up by 37% YoY but it is down by 30% QoQ
The return on invested capital has declined by 15% year-on-year and by 6% since the previous quarter
The company's return on assets rose by 6% YoY but it fell by 5% QoQ
The ROS fell by 6% QoQ and by 5% YoY
Dividends
What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAGX.
Financial health
How did Jaguar Health financials performed over time
JAGX's total assets is 7% greater than its total liabilities
JAGX's quick ratio has dropped by 67% year-on-year and by 49% since the previous quarter
Jaguar Health's current ratio has decreased by 43% YoY and by 34% from the previous quarter
The equity has shrunk by 85% YoY and by 76% QoQ
JAGX's debt is up by 15% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.